Background {#Sec1}
==========

Severe complicated intra-abdominal sepsis (SCIAS) imparts a mortality risk of 30-40% when individuals present in shock, even with the most advanced care \[[@CR1]--[@CR3]\]. For those who survive, hospitalization is often prolonged and fraught with complications including respiratory failure, renal failure, major cardiac events, wound infections, deep space infections, thromboembolic disease, neurocognitive dysfunction, and prolonged weakness. The high incidence of SCIAS compounds the complexity of care required to treat the disease and its complications, creating a large resource burden for health systems globally. Estimates of the cost of standard care per case in the Netherlands was 86,077 USD in 2010; in Austria, the effective cost "per survivor" was reported as 232,400 USD in 1998 \[[@CR4], [@CR5]\].

After initial surgery for SCIAS, in the absence of an absolute indication to leave the abdomen open (for example, bowel left in discontinuity), the fascia is usually closed definitively. With this approach, repeat unplanned laparotomy is commonly required to establish surgical source control \[[@CR6]\]. Early closure of the fascia can also lead to abdominal compartment syndrome with impairment of ventilation and renal perfusion.

An alternate strategy of leaving the fascia open ("open abdomen", OA) with active negative pressure peritoneal therapy (ANPPT) is being studied in an international, multisite-randomized controlled trial (Closed Or Open after Laparotomy, COOL); the comparator is standard fascial closure at the initial operation \[[@CR7]\]. Investigators hypothesize that ANPPT will allow for ongoing drainage of infected, inflammatory peritoneal fluid, decreasing the systemic propagation of inflammatory mediators \[[@CR8], [@CR9]\]. OA will also facilitate repeat operative washouts; these advantages may improve survival. Both approaches are acceptable options for the management of SCIAS according to World Society of Emergency Surgery guidelines \[[@CR10], [@CR11]\]. Despite varied expert opinion on the merits of the OA approach, an examination of the evidence base reveals persistent equipoise. Even if an OA strategy demonstrates clinical benefit in this trial, costs may be significantly higher in this approach due to increased need for critical care resources, including mechanical ventilation, while the fascia is open \[[@CR4]\]. Alternatively, costs may be lower if OA with ANPPT results in rapid resolution of systemic inflammation and a shortened duration of critical illness.

If the OA strategy shows clinical benefit, the resources required to adopt it into practice must be accurately counted; each resource used, including operating room and ICU time, comes with an opportunity cost (i.e., less resources available for other medical treatments). We therefore propose a 1-year prospective cost-utility analysis with robust quality of life valuation to be performed alongside this RCT, using decision analysis to extrapolate beyond 1 year if required. Since the economic implications of this strategy may be large, determining the incremental cost effectiveness ratio of this alternate therapy is important to guide adoption in any resource-constrained health care environment.

Objectives {#Sec2}
==========

Primary Objective {#Sec3}
-----------------

The primary objective of this analysis is to estimate the incremental cost-effectiveness ratio of the open abdomen (OA) approach versus fascial closure for SCIAS over the 1-year time horizon of the COOL trial. Resource use data will be requested from all study sites, and total cost estimates will be established based on unit costs derived from microcosting data from Calgary, Alberta.

If all outcomes are similar in the COOL trial, the analysis will instead default to a cost-minimization approach.

Secondary objectives {#Sec4}
--------------------

Secondarily, we aim to determine mean total cost difference for OA versus primary fascial closure for both the overall cohort and for pre-specified subgroups of patients including: Patients with and without the presence of septic shock at the time of initial surgeryAPACHE II score \> 20 or ≤ 20

Further, we will assess quality of life (QOL) after surgical management of SCIAS, identifying determinants of poor quality of life across the study population and quantifying differences in QOL between the two treatment arms.

Finally, if neither operative strategy is dominant (i.e., if greater costs and improved outcomes accrue in one treatment arm), we will conduct a Markov analysis to determine the cost per quality-adjusted life years gained over a lifetime horizon. We will estimate the incremental cost-effectiveness ratio and create a cost-effectiveness acceptability curve using Monte Carlo simulation.

Methods {#Sec5}
=======

COOL study {#Sec6}
----------

The methodology of the COOL trial has been published elsewhere \[[@CR7]\] and is briefly summarized here. To be included in the trial, adult patients will have complicated intra-abdominal infection (purulent, feculent, or enteric contents in the peritoneal cavity at the time of operation) and present with severe disease (either septic shock, World Society of Emergency Surgery Sepsis Severity Score ≥ 8, or a Calgary Predisposition-Infection-Response-Organ dysfunction score ≥ 3). Patients will be excluded if presenting during pregnancy, if there is a perceived inability to close the abdomen safely without inducing intra-abdominal hypertension, or if there is an absolute indication for "damage control laparotomy," among other exclusion criteria. Patients in the *intervention* arm of the trial will have the abdomen temporarily closed with an ABTHERA^TM^ device with planned repeat operation 24-72 h later. In the *control* arm, the fascia will be closed in the usual fashion after a closed-suction intraperitoneal drain is placed. Randomization will be performed online after confirming eligibility, with a permuted block randomization strategy to ensure close balance between treatment arms at each site.

Population for COOL-cost {#Sec7}
------------------------

For the primary cost analysis, the patient population will include all patients randomized to open abdomen (OA) or primary fascial closure in the COOL trial.

Data on resource use will be requested from all participating sites. Microcosting data from Calgary, Alberta, will be used to establish unit costs and develop estimated cost totals.

Identification, measurement, and valuation of resource use {#Sec8}
----------------------------------------------------------

All costs that may differ between study arms will be considered from a publicly-funded health care payer perspective using a microcosting approach where possible (Table [1](#Tab1){ref-type="table"}). Costs can be divided into those associated with the index hospitalization, follow-up care, any required readmission or delayed inpatient surgical procedure, and day medicine and surgery encounters (Table [2](#Tab2){ref-type="table"}). Table 1Microcosting in the Calgary zone, Alberta Health Services*Microcosting in Alberta*To determine how costs differ between treatment arms in this analysis, we will use microcosting \[[@CR12]\] data from hospitals in the Calgary Zone of Alberta Health Services. Resources used in the management of each patient will be enumerated, valued, and summed to create a highly precise cost-of-care for each individual. Less intensive methodologies using average patient costs for similar groups would be insensitive to the differences in cost between the open abdomen and primary fascial closure arms.Microcosting is made possible by patient-specific resource use data collected by Alberta Health Services and calculated in accordance with national Management Information Systems guidelines \[[@CR13]\]. First, the quantity of physical materials and diagnostics necessary for the care of each patient are tracked. These include medications, blood products, patient-traceable disposables, radiologic investigations, and laboratory tests. The quantity of each is multiplied by the unit cost (estimated annually) to provide a total cost estimate and these are summed. The direct human resources required for care including nursing and support staff are quantified and similarly costed. Physician billing fees are added to this to create a total cost of labor. The indirect costs of the spaces and systems of care (e.g., ICU bed or OR time) are then apportioned to each patient \[[@CR12]\]. Costs across these domains are summed to create an estimate of cost for each patient encounter. Outpatient encounter data are also available to estimate the cost of follow-up with specialists, rehabilitation, and outpatient services such as dialysis.The availability and quality of cost data reporting in Alberta is highly regarded and has previously been used in the assessment of surgical costs \[[@CR14]\]. Our primary analysis will combine resource use data from all COOL sites with microcosting data from Calgary to create estimates of cost in each treatment arm.Table 2Microcosting data items required from Calgary, Alberta sitesVariableDescriptionData requiredData source*Baseline/Admission data*Patient unique identifierSingle datum permitting linkage across multiple databasesUnique Lifetime IdentifierCOOL trialHospital at enrolmentHospital where initial laparotomy is performedSite nameCOOL trialPatient postal codeApproximate location of patient's domicile (necessary for calculating transportation costs)Postal codeCOOL trialPatient ageIn yearsAge in yearsCOOL trialPatient sexMale, female, otherSexCOOL trialICD-10 admission diagnosisSingle admission diagnosisICD-10 codeCOOL trialShock at the time of initial ORHypotension requiring pressors for MAP \> 65 or serum lactate \> 2 mmol/L after resuscitationYes/NoCOOL trialAdmission APACHE II scoreSeverity-of-disease classification scoreScore at time of admissionCOOL trial*Index hospitalization*Operating roomDates of each operating room encounterDuring index hospitalizationList of datesCOOL trialProcedures performed at each operating room encounterAll procedure codes includedList of procedure codesCOOL trialDuration of all operating room encountersDocumented entry into and exit from operating roomTime in minutesCOOL trialAnesthetist billings associated with each operating room encounterTotal physician claimsBillings in CADAlberta Medical Association (AMA) fee scheduleSurgeon billings associated with each operating room encounterTotal physician claimsBillings in CADAMA fee scheduleOperating room drug costsList, quantity, and cost of all medications used during surgeryMedications and costsFinance oracle microcosting database (Oracle)List and quantity of disposables used at each surgical encounterAll non-sterilizable surgical tools designed for one-time use, as well as suture materials and dressingsList and quantityOracleSurgical instrument sets used at each surgical encounterName of each set used (e.g., major abdominal)List of instrument setsOraclePostoperative careLength of stay in ICU and costStay in a designated critical care environmentLength in daysCOOL trial, OracleLength of stay on general ward and costLength of hospital stay, less the length of ICU stayLength in daysCOOL trial, OracleLength of stay in post-anesthesia care unitStay in a designated PACULength in daysOracleDirect and indirect costs of PACU stayItemized cost of PACU stay including personnel, disposables, medications, and overhead costsCosts in CADOraclePhysician billings associated with hospital stayTotal Alberta Health billings, less surgeon, and anesthetist operative billingsBillings in CADAHS data analytics (DIMR)Postoperative diagnostic imaging costsTotal of per-study fees, plus the AHS billings of diagnostic radiologistsCosts in CADOraclePostoperative percutaneous procedure costsTotal of per-procedure fees, plus the AHS billings of interventional radiologistsCosts in CADOracleCosts of laboratory testingTotal in-hospital laboratory testing, less total study-specific laboratory testing costsCosts in CADOracleInpatient drug costsTotal pharmaceutical costsCosts in CADOracleCost of blood products usedTotal cost of in-hospital blood product useCosts in CADOracleCost of nursing and allied health care not included in per-diem unit costTotal cost of specialized RN and other allied health providersCosts in CADOracleCost of disposables used in postoperative patient careTotal cost of disposablesCosts in CADOracle*Follow-up care*Number of surgeon visits (to 1 year)Regardless of reason for visitNumber of visitsDIMRNumber of other specialist physician visits (to 1 year)Regardless of reason for visitNumber of visitsDIMRTotal outpatient AHS billingsRegardless of reason for servicesBillings in CADDIMR*Readmissions*Number and length of each readmission within 1 yearRegardless of reason for readmissionNumber and length in daysDIMRTotal hospital cost, including physician billings, associated with each readmissionRegardless of reason for visitCosts in CADDIMR*Subsequent OR costs*Dates of each operating room encounter within 1 yearAfter index hospitalizationList of datesCOOL trialProcedures performed at each operating room encounterAll procedure codes includedList of procedure codesCOOL trialDuration of all operating room encountersDocumented entry into and exit from operating roomTime in minutesCOOL trialAnesthetist billings associated with each operating room encounterTotal physician claimsBillings in CADAMA Fee ScheduleSurgeon billings associated with each operating room encounterTotal physician claimsBillings in CADAMA Fee ScheduleList and quantity of disposables used at each surgical encounterAll non-sterilizable surgical tools designed for one-time use, as well as suture materials and dressingsList and quantityOracleSurgical instrument sets used at each surgical encounterName of each set used (e.g., major abdominal)List of instrument setsOracle*Ambulatory care costs*Number, type, and cost of all other ambulatory encounters (other than family physician and specialist encounters)All day medicine and day surgery encounters (including dialysis) within one yearNumber, type, and costs in CADDIMR*Costs to patients and caregivers*Cost of transportation to and from family physician and specialist appointmentsTotal estimated costsNumber of visits, approximate distance to domicileDIMR*Productivity costs*Number of days absent from work at 1 yearSelf-reported number of days absent from workTotal daysCOOL trial*Outcomes*Mortality at 90 daysPrimary outcomeDichotomous variableCOOL trialMortality at 1 yearLong-term survivalDichotomous variableCOOL trialPresence of a stoma at initial hospital dischargeIleostomy or colostomyDichotomous variableCOOL trialPresence of a stoma at 90 days and 1 yearIleostomy or colostomyDichotomous variableCOOL trialEQ-5D-5 L and SF-36 at 90 daysValidated quality of life measureValues at 90 daysCOOL trialEQ-5D-5 L and SF-36 at 1 yearValidated quality of life measureValues at one yearCOOL trial

A secondary analysis from a societal perspective will be conducted if the data permit. This will include nonmedical and patient-borne costs attributable to the illness and associated care, and the value of lost productivity.

### Index hospitalization costs {#Sec9}

First, we will consider the costs of surgery for the alternate strategies. The number of minutes spent in the operating room, care by surgeons and anesthesiologists, and the use of sterilizable surgical tools will be valued and included. The cost of surgical disposables will be included; while temporary abdominal closure devices may be provided free-of-charge by the manufacturer for use in the trial, the market value of these devices will be determined and included.

Postoperatively, the cost of care provided in the post-anesthesia care unit, intensive care unit (ICU), and the general ward will be determined and included. The costs of care in ICU are hypothesized to represent a large proportion of the inpatient costs for SCIAS patients and may drive differences in cost between the two treatment arms. In the Canadian context, ICU care costs are approximately three times higher than that on a general ward, and so ICU length of stay and costs will be specifically examined in this analysis \[[@CR15]\].

The microcosting approach will provide data on the cost of nursing care, diagnostic imaging, percutaneous interventions, laboratory testing (excluding additional testing performed solely for trial purposes), medications including antibiotics, blood products, additional care provided by other health providers including physiotherapy, occupational therapy, and enterostomal therapists, and the costs of disposables required for care in hospital. Furthermore, data will be provided on indirect costs such as patient transport, housekeeping, administration, and building maintenance. These costs will be summed and included in the primary analysis.

### Follow-up care costs {#Sec10}

We will include the costs of follow-up with specialist physicians and enterostomal therapists, the management of wound infections, time spent in a rehabilitation facility, and the cost of any ongoing organ support such as hemodialysis for renal failure.

### Readmissions {#Sec11}

If readmission to hospital within one year is required for any reason, this will be recorded. Given that the relevance of a readmission to the original illness is difficult to determine, the full cost of readmissions will be included in the primary analysis. In a secondary analysis, if it is possible to determine which admissions (or portions thereof) are unrelated to the original illness, these will be excluded.

### Surgical procedures after initial discharge {#Sec12}

All surgical procedures within 1 year will be costed and included in the primary analysis. In secondary analysis, only surgeries related to the diagnosis of SCIAS will be included, which might include reversal of an enterostomy, management of an enterocutaneous fistula, or management of an abdominal hernia.

### Ambulatory case costing {#Sec13}

We will identify, cost, and include all related outpatient day surgery, day medicine, and emergency room visits occurring after discharge.

### Costs to patients and caregivers {#Sec14}

After discharge from hospital, the cost of transportation to and from health care providers will be estimated for each patient by multiplying the number of follow-up visits by the distance traveled to and from the listed home address and using a standard per-kilometer cost value. These costs will be included in secondary analysis from a societal perspective.

### Productivity costs {#Sec15}

Absence from paid work after a diagnosis of SCIAS may have significant economic consequences. The number of days absent from paid work after discharge will be tabulated for all individuals less than 65 years of age, and the value of this absence will be calculated using a friction cost methodology and included in secondary analysis \[[@CR16]\].

Quality of life {#Sec16}
---------------

Quality of life data are being collected in the COOL trial as a secondary outcome, using the Euroqol EQ-5D-5 L and SF-36 surveys at 6 months and 1 year postoperatively. Utility values will be estimated using the EQ-5D-5 L index score, using the visual analog score as a secondary analysis. We will assess quality of life data across the study population to identify drivers of good or poor quality of life at the 6-month and 1-year mark. We will then quantify differences in quality of life between the OA and fascial closure arms.

Cost-effectiveness analysis alongside the trial in year 1 {#Sec17}
---------------------------------------------------------

Total quality-adjusted life years at the 1-year mark will be determined for each individual in the trial using mortality and QoL data. The incremental cost-effectiveness ratio (ICER) will be calculated as: $$\documentclass[12pt]{minimal}
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where *C*~OA~ is the mean cost of the open abdomen strategy, *C*~PFC~ is the mean cost in the standard-of-care primary fascial closure strategy, *Q*~OA~ is the value of quality-adjusted life years (QALYs) associated with surgery with an open abdomen strategy, and *Q*~PFC~ is the value of QALYs associated with the primary fascial closure strategy.

The ICER will be expressed in 2020 CAD per QALY. A bootstrapping approach using sampling with replacement will be used to create an overall estimate of the ICER with confidence intervals based on 1000 samples from the study population.

Modeling of cost-effectiveness beyond 1 year {#Sec18}
--------------------------------------------

If neither the OA or fascial closure strategy is economically dominant (i.e., better outcomes but also higher costs accruing in one treatment arm), Markov modeling will be used to estimate cost, QALYs, and cost per QALY gained at the 2-, 5-, 10-year, and lifetime horizons.

To perform this analysis, a set of mutually exclusive, collectively exhaustive health states after surgery for SCIAS will be determined. These might include, for example, complete recovery, recovery with ileostomy or colostomy, chronic dependence on renal replacement therapy, neurologic impairment due to stroke or complications of critical illness, and death. The transition probabilities between these health states will be estimated using existing literature, COOL study data, and locally available datasets. A cycle length of 1 year will be used. Each health state will be assigned utility values. Across a simulated population of patients, total QALYs gained and additional costs accrued (from, for example, further surgery), as well as the cost per QALY, will be estimated. Future costs and benefits will be discounted at 1.5% per annum.

Monte Carlo simulation will then be used to determine a cost-effectiveness acceptability curve.

Sample size and power {#Sec19}
---------------------

A limitation in conducting a cost-effectiveness analysis in the context of an RCT is that trials are powered to demonstrate differences in clinical outcome and not necessarily differences in cost between treatment arms. In this case, power will also be limited by costing resources within the population of patients recruited in Calgary, Canada---meaning less variability in costing estimates.

This limitation in power will be mitigated by using extensive sensitivity and scenario analyses including the above bootstrapping approach to define a cost effectiveness acceptability curve.

Compliance with reporting guidelines and methodological literature {#Sec20}
------------------------------------------------------------------

This analysis follows CADTH (Canadian Agency for Drugs and Technologies in Health) guidelines for the economic evaluation of health technologies \[[@CR17]\]. The reference case we plan to use is a cost-utility analysis. The intervention and its standard-of-care comparator are clearly delineated, and the setting for the economic analysis has been established. We will use a publicly-funded health care payer perspective over a lifetime horizon, with future discounting of costs and benefits at 1.5%. Subgroups with potentially differing costs and benefits have been prespecified. We will include all relevant costs; effectiveness, including quality of life valuation, will be provided by the outcomes of the COOL trial. The results of this analysis will be reported following existing guidelines.

Discussion {#Sec21}
==========

The COOL trial is being conducted in centers around the world, giving rise to a diverse study population and clinically generalizable results. We plan to incorporate all available data on health resource use from global sites, and, combined with unit cost data from the Calgary microcosting environment, establish estimates of total cost for each treatment arm. This approach accounts for differing health resource use at all study sites while creating a single estimate of the ICER that can be used by clinicians and hospital leaders in evaluating the OA strategy. However, it does not account for how the economic context might differ between the countries and centers in which the trial is being conducted; unit costs of specific health resources may differ significantly. For resources that are found to be the main drivers of cost, we will therefore obtain unit costs from all sites and conduct extensive sensitivity analyses. Through these sensitivity analyses, we will create a more complete picture of the incremental cost-effectiveness ratio in individual sites where costs and even outcomes may differ.

Conclusions {#Sec22}
===========

To date, the cost of managing patients using an open-abdomen ANPPT approach compared with managing patients using SCIAS remains unknown. The COOL trial has begun to recruit participants and full accrual is anticipated by December, 2023. If the trial demonstrates improved outcomes with an OA strategy, accurate estimation of the cost-effectiveness of this approach will be necessary prior to its widespread adoption. Our proposed analysis will address this critical question.

ANPPT

:   Active negative pressure peritoneal therapy
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:   Canadian Agency for Drugs and Technologies in Health
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:   Closed Or Open after Laparotomy
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:   Open abdomen
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:   Quality-adjusted life year
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:   Quality of life

SCIAS

:   Severe complicated intra-abdominal sepsis
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